IL-2联合HCPT预防复发浅表膀胱癌术后再复发疗效观察

摘要

目的:了解免疫制剂白介素2 (IL-2)与植物制剂化疗药羟基喜树碱(HCPT)联合膀胱灌注降低浅表膀胱癌术后再复发机率的效果.方法:将62例有膀胱癌手术史(48例行了TURBt术,14例行了膀胱部分切除术),术后2年内复发均再行了TURBt术的患者随机分为:(1) IL-2 + HCPT组(n=31),(2) HCPT组(n=31),比较分析两组间术后再复发机率.结果:(1)膀胱灌注半年后,两组患者的CT检查及膀胱镜检证实再复发例数分别为0例(0%)、1例(3.2%),差异不显著(P>0.05);(2)膀胱灌注1年后,两组患者的CT检查及膀胱镜检证实再复发例数分别为1例(3.2%)、8例(25.8%),差异有显著性(P<0.05);(3)膀胱灌注2年后,两组患者的CT检查及膀胱镜检证实复发例数分别为4例(12.9%)、15例(48.4%),差异有显著性意义(P<0.05).结论:IL-2联合HCPT膀胱灌注有助于降低浅表膀胱癌术后再复发机率.%Objective:To evaluate the effect of intravesical instillation of IL-2 together with HCPT in the prevention of recurrence of recurrent bladder cancer. Methods:To divide 62 patients undergone TURBt for recurrent bladder cancer into two groups:A group(31 cases) -intravesical instillation with IL-2 + HCPT for recurrent bladder cancer, B group(31 cases) -intravesical instillation with HCPT for recurrent bladder cancer. To study the therapeutic effect between two groups by analyzing the ratio of recurrence of recurrent bladder cancer. Results:After treatment for 6 months, 12 months,24 months,the ratio recurrence of IL-2 + HCPT group is 0%,3.2%,12.9%,being lower than that in HCPT group (3.2%,25.8%,48.4%),respectively.The differences of the ratio of tumor recurrence for 12 months,24 months after operation between two groups are obvious (P<0.05). Conclusion:Intravesical instillation of IL-2 together with HCPT may be useful in the prevention of recurrence of recurrent bladder cancer.